

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

**宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

**VOLUNTARY ANNOUNCEMENT  
INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR,  
CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD**

This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the **“Company”**, together with its subsidiaries, the **“Group”**) on a voluntary basis to inform shareholders and potential investors of the Company in relation to the increase in shareholding in the Company by Dr. Tian Wenzhi (**“Dr. Tian”**), an executive director, the chief executive officer and the chairman of the board of directors of the Company (the **“Board”**).

The Board was informed by Dr. Tian that he has purchased a total of 50,000 H shares of the Company in the open market on December 3, 2025, at an average price of approximately HK\$6.6258 per Share, representing approximately 0.01% of the total issued shares (the **“Shares”**) of the Company. Immediately after the purchase, Dr. Tian is interested in an aggregate of 116,134,090 Shares, representing 26.91% of the total issued Share capital of the Company as at the date of this announcement.

As advised by Dr. Tian, he is fully confident about the overall development prospects and potential growth of the Group. Subject to compliance with applicable laws and regulatory requirements, Dr. Tian does not rule out that he may further increase his shareholding in the Company as and when appropriate.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
**宜明昂科生物醫藥技術（上海）股份有限公司**  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, December 3, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*